The Motley Fool··James BrumleyCRISPR Stock Plunges 12% on $350M Convertible Debt Offering
CRISPR Therapeutics stock fell 12% after announcing a $350M convertible debt offering. Analysts remain bullish, suggesting the decline may present a buying opportunity.
CRSPstock declineshareholder dilution